Silva J E, Leonard J L, Crantz F R, Larsen P R
J Clin Invest. 1982 May;69(5):1176-84. doi: 10.1172/jci110554.
Propylthiouracil (PTU) is a well known inhibitor of thyroxine (T(4)) to triiodothyronine (T(3)) conversion as evidenced by its effect in several in vitro systems and by the decrease in serum T(3) caused by this drug in either rats or man receiving T(4) replacement. However, the failure of PTU to decrease the intrapituitary T(3) concentration and to completely blunt the serum T(3) concentration in T(4)-replaced athyreotic rats suggest that there may be a PTU-insensitive pathway of T(4) to T(3) conversion in some tissues. To address this question, we have studied the in vivo effect of PTU treatment on the generation of [(125)I]T(3) from [(125)I]T(4) in the serum and cerebral cortex (Cx), cerebellum (Cm), liver (L), and anterior pituitary (P) of euthyroid rats. Whereas PTU decreased the concentration of [(125)I]T(3) in the serum, L homogenates, and L nuclei after [(125)I]T(4), it did not affect the concentration of [(125)I]T(3) in homogenates or nuclei of Cx, Cm, or P. Iopanoic acid pretreatment significantly reduced the [(125)I]T(3) concentration in serum, homogenates, and cell nuclei of all these organs. Neither agent affected the metabolism or tissue distribution of simultaneously injected [(131)I]T(3). The presence of PTU in these tissues was evaluated by in vitro assessment of iodothyronine 5'-deiodinating activity using both [(125)I]rT(3) and [(125)I]T(4) as substrates. In agreement with the in vivo findings, generation of [(125)I]T(3) from T(4) in vitro was not affected by PTU in Cx, Cm, P but it was inhibited by 76% in L. However, rT(3) 5'-deiodination, known to be sensitive to PTU in these tissues, was inhibited in all four indicating that the PTU given in vivo was present in significant amounts. These results demonstrate that in rat Cx, Cm, and P unlike liver, PTU does not inhibit T(4) to T(3) conversion in vivo despite the presence of the drug in the tissues in amounts that significantly inhibit reverse T(3) 5'-deiodination. These results show that in vivo 5'-deiodination of T(4) proceeds via a PTU-insensitive pathway in the central nervous system and pituitary, while this pathway is not quantitatively important in the L. This mechanism accounts for the "locally generated" T(3) in central nervous system and pituitary and could also provide the approximately one-third of extrathyroidally produced T(3) not blocked by PTU administration in athyreotic T(4)-replaced rat.
丙硫氧嘧啶(PTU)是一种众所周知的甲状腺素(T4)向三碘甲状腺原氨酸(T3)转化的抑制剂,这在多个体外系统中得到了证实,并且在接受T4替代治疗的大鼠或人类中,该药物会导致血清T3降低。然而,PTU未能降低甲状腺切除并用T4替代的大鼠垂体中的T3浓度,也未能完全抑制血清T3浓度,这表明在某些组织中可能存在一条对PTU不敏感的T4向T3转化途径。为了解决这个问题,我们研究了PTU处理对正常甲状腺大鼠血清、大脑皮层(Cx)、小脑(Cm)、肝脏(L)和垂体前叶(P)中[125I]T3从[125I]T4生成的体内影响。尽管PTU降低了[125I]T4处理后血清、L匀浆和L细胞核中[125I]T3的浓度,但它对Cx、Cm或P的匀浆或细胞核中[125I]T3的浓度没有影响。碘番酸预处理显著降低了所有这些器官的血清、匀浆和细胞核中[125I]T3的浓度。两种药物均未影响同时注射的[131I]T3的代谢或组织分布。通过使用[125I]反T3(rT3)和[125I]T4作为底物对碘甲状腺原氨酸5'-脱碘活性进行体外评估,来评估这些组织中PTU的存在情况。与体内研究结果一致,在体外,Cx、Cm、P中T4生成[125I]T3不受PTU影响,但在L中受到76%的抑制。然而,已知在这些组织中对PTU敏感的rT3 5'-脱碘作用在所有四个组织中均受到抑制,这表明体内给予的PTU大量存在。这些结果表明,在大鼠的Cx、Cm和P中,与肝脏不同,尽管组织中存在能显著抑制反T3 5'-脱碘作用的PTU量,但PTU在体内并不抑制T4向T3的转化。这些结果表明,在体内,T在中枢神经系统和垂体中通过一条对PTU不敏感的途径进行5'-脱碘,而这条途径在肝脏中在数量上并不重要。这种机制解释了中枢神经系统和垂体中“局部生成”的T3,也可能是甲状腺切除并用T4替代的大鼠中未被PTU给药阻断的约三分之一的甲状腺外产生的T3的来源。